Susannah Brock

Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial

Nicholas D. James, Matthew R. Sydes, Noel W. Clarke et al. · The Lancet · 2015 · 2K citations · Full text

Medicine, Oncology, Urology +17

Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy

Nicholas D. James, Johann S. de Bono, Melissa Spears et al. · New England Journal of Medicine · 2017 · 1.8K citations · Full text

Medicine, Oncology, Urology +14

Adding abiraterone or docetaxel to long-term hormone therapy for prostate cancer: directly randomised data from the STAMPEDE multi-arm, multi-stage platform protocol

Matthew R. Sydes, Melissa Spears, Malcolm D. Mason et al. · Annals of Oncology · 2018 · 250 citations · Full text

Medicine, Oncology, Urology +17

A Comparison of the Patterns of Migration and the Destinations of Homotopically Transplanted Neonatal Subventricular Zone Cells and Heterotopically Transplanted Telencephalic Ventricular Zone Cells

Tanja Zigova, Ranjita Betarbet, B. J. Soteres et al. · Developmental Biology · 1996 · 98 citations

Life Sciences, Neurobiology, Neuroscience +8

Abiraterone acetate plus prednisolone for metastatic patients starting hormone therapy: 5‐year follow‐up results from the STAMPEDE randomised trial (NCT00268476)

Nicholas D. James, Noel W. Clarke, Adrian Cook et al. · International Journal of Cancer · 2022 · 77 citations · Full text

Medicine, Oncology, Pharmacotherapy +17